1 Pharm D Intern Nazareth College of Pharmacy, Othera, Kerala, India.
2 Associate Professor, Department of General Medicine, Believers church medical college hospital, Thiruvalla, Kerala, India.
3 Clinical Pharmacist Believers Church Medical College Hospital, Kerala, India.
World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 111–113
Article DOI: 10.30574/wjbphs.2025.21.2.0114
Received on 19 December 2024; revised on 31 January 2025; accepted on 02 February 2025
Depression and nightmares are caused by Montelukast. Montelukast is a selective leukotriene receptor antagonist (LRTA) and US-FDA issued a black box warning in 2020. In this case report, a 14 year old female was prescribed a combination of Tab. Montelukast and Tab. Fexofenadine for the treatment of bronchial asthma exacerbations. After this, she started experiencing multiple episodes of depression and nightmares. The patient was asked to avoid Montelukast after which the patient's condition improved and she was started on MDI Formoterol fumarate and Budesonide powder for inhalation and Tab. Desloratadine for further management. After stopping the drug, her condition improved. This case report underlines the importance of monitoring for rare but serious side effects of leukotriene receptor antagonist and highlights the need for further research into their mechanisms and risk factors.
Montelukast; Depression; Nightmare; Bronchial asthma; Fexofenadine
Preview Article PDF
VIJI MARY CHRISTEENA, ABRAHAM JACOB THOMAS and S HARIKRISHNAN. A case report on montelukast and fexofenadine induced depression and nightmares. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 111–113. Article DOI: https://doi.org/10.30574/wjbphs.2025.21.2.0114
Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0